200 related articles for article (PubMed ID: 25144909)
1. The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.
Stein BD; Leckman-Westin E; Okeke E; Scharf DM; Sorbero M; Chen Q; Chor KH; Finnerty M; Wisdom JP
J Child Adolesc Psychopharmacol; 2014 Sep; 24(7):374-81. PubMed ID: 25144909
[TBL] [Abstract][Full Text] [Related]
2. Second-Generation Antipsychotic Prescribing Patterns for Pediatric Patients Enrolled in West Virginia Medicaid.
Melvin KE; Hart JC; Sorvig RD
Psychiatr Serv; 2017 Oct; 68(10):1061-1067. PubMed ID: 28566023
[TBL] [Abstract][Full Text] [Related]
3. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
Spence O; Reeves G; dosReis S
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.
Akincigil A; Mackie TI; Cook S; Hilt RJ; Crystal S
Health Serv Res; 2020 Aug; 55(4):596-603. PubMed ID: 32567089
[TBL] [Abstract][Full Text] [Related]
5. The Impact of a State Medicaid Peer-Review Authorization Program on Pediatric Use of Antipsychotic Medications.
Pennap D; Burcu M; Safer DJ; Zito JM
Psychiatr Serv; 2018 Mar; 69(3):293-299. PubMed ID: 29137557
[TBL] [Abstract][Full Text] [Related]
6. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
Law MR; Ross-Degnan D; Soumerai SB
Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
[TBL] [Abstract][Full Text] [Related]
7. Restrictions on antidepressant medications for children: a review of Medicaid policy.
Fischer MA; Servi AD; Polinski JM; Wang PS
Psychiatr Serv; 2007 Jan; 58(1):135-8. PubMed ID: 17215425
[TBL] [Abstract][Full Text] [Related]
8. Differences in Medicaid Antipsychotic Medication Measures Among Children with SSI, Foster Care, and Income-Based Aid.
Leckman-Westin E; Finnerty M; Scholle SH; Pritam R; Layman D; Kealey E; Byron S; Morden E; Bilder S; Neese-Todd S; Horwitz S; Hoagwood K; Crystal S
J Manag Care Spec Pharm; 2018 Mar; 24(3):238-246. PubMed ID: 29485947
[TBL] [Abstract][Full Text] [Related]
9. Impact of a prior authorization policy for montelukast on clinical outcomes for asthma and allergic rhinitis among children and adolescents in a state Medicaid program.
Keast SL; Thompson D; Farmer K; Smith M; Nesser N; Harrison D
J Manag Care Spec Pharm; 2014 Jun; 20(6):612-21. PubMed ID: 24856599
[TBL] [Abstract][Full Text] [Related]
10. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
11. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
[TBL] [Abstract][Full Text] [Related]
12. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.
Zhang Y; Adams AS; Ross-Degnan D; Zhang F; Soumerai SB
Psychiatr Serv; 2009 Apr; 60(4):520-7. PubMed ID: 19339328
[TBL] [Abstract][Full Text] [Related]
13. Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018.
Candon M; Shen S; Fadeyibi O; Smith JL; Rothbard A
BMC Psychiatry; 2021 Oct; 21(1):524. PubMed ID: 34686159
[TBL] [Abstract][Full Text] [Related]
14. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
15. Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.
Chavez LJ; Kelleher KJ; Beck A; Clarke GN; Penfold RB
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):381-386. PubMed ID: 34143677
[No Abstract] [Full Text] [Related]
16. Quality Measures for Managing Prescription of Antipsychotic Medication Among Youths: Factors Associated With Health Plan Performance.
Olin S; Storfer-Isser A; Morden E; Yin Y; Altamirano L; Byron SC; Scholle SH
Psychiatr Serv; 2019 Nov; 70(11):1020-1026. PubMed ID: 31337323
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.
Zito JM; Burcu M; Ibe A; Safer DJ; Magder LS
Psychiatr Serv; 2013 Mar; 64(3):223-9. PubMed ID: 23242390
[TBL] [Abstract][Full Text] [Related]
18. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
Fischer MA; Schneeweiss S; Avorn J; Solomon DH
N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotics in the California Foster Care System: A 10-Year Analysis.
Nunes JC; Naccarato T; Stafford RS
J Child Adolesc Psychopharmacol; 2022 Sep; 32(7):400-407. PubMed ID: 35834606
[No Abstract] [Full Text] [Related]
20. Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015.
Hulkower RL; Kelley M; Cloud LK; Visser SN
Public Health Rep; 2017; 132(6):654-659. PubMed ID: 29072963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
